Catabasis Pharmaceuticals Inc (NASDAQ:CATB) saw unusually-strong trading volume on Monday . Approximately 5,523,600 shares changed hands during trading, an increase of 322% from the previous session’s volume of 1,309,994 shares.The stock last traded at $1.60 and had previously closed at $1.39.
CATB has been the subject of a number of research analyst reports. Citigroup upgraded Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Monday, November 20th. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research report on Thursday, November 16th. Finally, Wedbush reiterated an “outperform” rating and set a $4.00 price target (down previously from $5.00) on shares of Catabasis Pharmaceuticals in a research report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $4.82.
The stock has a market capitalization of $36.01 and a PE ratio of -1.03.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.